Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/89806
標題: Anti-enterovirus 71 compounds from Ficus pumila L. fractions
薜荔區分物抗腸病毒71型活性成分之研究
作者: Ren-Jie Zhang
張仁傑
關鍵字: Ficus pumila L.
Enterovirus 71
time-of-addition analysis
薜荔
腸病毒71型
時間點分析
引用: 毛彩霓、楊衛麗、劉明生。薜荔藥材兩種提取物的抗炎作用研究。海南醫學院學報。2010; (10), 1256-1258。 王世敏、劉清泉。台灣腸病毒71型感染的回顧與展望。醫療品質雜誌。2009; 3(3), 37-41。 王世敏、劉清泉。台灣的腸病毒研究。科學發展。2012; (475), 32-36。 王啟釗、呂穎慧、李招發、刁 勇、許里安。腺相關病毒的衣殼裝配和DNA衣殼化機制。生物工程學報。2011; (04), 531-538。 史清文、李力更、霍長虹、張嫚麗、王于方。天然藥物化學研究與新藥開發。中草藥。2010; (10), 1583-1589。 江大雄、賴辛癸、陳國東、王躬仁。腸病毒的流行病學概論。疫情報導。1999; 15(3), 89-102。 何顏霞、付 丹。EV71感染相關神經源性肺水腫和心肺衰竭。臨床兒科雜志。2008; 26(12), 1087-1090。 余世榮、周本宏、劉 芳。薜荔果本草考證及現代研究概況。中國藥師。2010; (09), 1343-1345。 吳文珊、方玉霖。薜荔瘦果的營養成分研究。自然資源學報。1999; (02), 51-55。 吳文珊、王揚飛、方玉霖、黃澤豪、吳淩雲、鄭翠芳。薜荔抑菌效應的研究。福建熱作科技。2004; (02), 15-16。 吳其濬。植物名實圖考 (輯校本)。商務印書館。1957。 李蘭娟、楊 敬、葉 真。手足口病。浙江科學技術出版社。2008。 林讚標、劉哲政、楊居源、黃瑞祥、李永生、張森永。愛玉與薜荔隱花果形態與其生化特性比較。林業試驗所研究報告季刊。1990; 5(1), 37-43。 苑翠柳。抗癌食果研究的新進展。林業科技通訊。1999; (06), 19-21。 范明松、葉冠、黃成鋼。榕屬植物化學成分和藥理作用研究進展。天然產物研究與開發。2005; (04), 497-504。 唐 煌、郭 琳、李玲敏、鐘書明、鄧勝平。小葉薜荔莖葉提取物的抗氧化活性研究。食品工業科技。2012; (10), 166-169。 唐翠娥、梁瑞紅、劉 偉、劉成梅。薜荔概述及研究進展。農產品加工。2007; (02), 18-19+25。 徐健、張玉梅、陳科力、譚寧華、劉義梅。黃葉扁柏枝葉中的一個新單萜苷。藥學學報。2012; (09), 1179-1182。 高 爽、龍健兒。腸道病毒71型的功能基因組學研究進展。生命科學。2012; (01), 43-49。 張軒豪。薜荔抗腸病毒71型活性成分之分離。國立中興大學食品暨應用生物科技研究所碩士學位論文。2012。 郭明裕。聖嬰現象下之腸病毒基因醫學探秘-謹以四年來對腸病毒基因醫學的努力探索與觀點獻給付出寶貴生命代價的腸病毒71型重症兒童。疫情報導。2003; 19(8), 425-432。 陳育如。薜荔抗腸病毒活性及其免疫調節作用之研究。國立中興大學食品暨應用生物科技研究所碩士學位論文。2010。 生物資源保存及研究中心 (BCRC)。細胞操作指引。http://classroom.bcrc.firdi.org.tw/home/cell。2013。 劉武哲。臨床病毒學檢驗手册。藝軒圖書出版社。2002 劉武哲。醫用病毒學及其研究方法 (修訂版)。台北。藝軒圖書出板社。2003。147-148頁。226-255頁。 戴海學、李曉蓉、李宇航、劉 蘊、薛 明。丹參酮ⅡA和丹參酮Ⅰ的電子轟擊與電噴霧電離質譜分析。分析試驗室。2008; (05), 24-29。 孫玉林、陳茵、徐新亞、張曉勇、鄭智慧、農旭華、鮑潔、漆淑華。海洋真菌Penicillium oxalicum SCSGAF 0023的次生代謝產物及其抗污損和酶抑制活性研究。天然產物研究與開發。2013; (01), 1-6+59。 Abd-Elazem, Ibrahim S., Chen, Hong S., Bates, Robert B., & Huang, Ru Chih C. Isolation of two highly potent and non-toxic inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase from Salvia miltiorrhiza. Antiviral Research. 2002; 55(1), 91-106. Bharanidharan, M., Sivasubramanian V., & Rama Raja Valli Nayagam, S. Evaluation of antioxidant and antimicrobial potential of cyanobacteria, Chroococcus turgidus (Kützing) Nägeli. Int. J Curr Microbiol App Sci. 2013; 2(10), 300-305. Arita, M., Nagata, N., Iwata, N., Ami, Y., Suzaki, Y., Mizuta, K., Iwasaki, T., Sata, T., Wakita, T., & Shimizu, H. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol. 2007; 81(17), 9386-9395. Arita, M., Takebe, Y., Wakita, T., & Shimizu, H. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. J Gen Virol. 2010; 91(Pt 11), 2734-2744. Arita, M., Wakita, T., & Shimizu, H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol. 2008; 89(Pt 10), 2518-2530. Barnard, D. L., Hubbard, V. D., Smee, D. F., Sidwell, R. W., Watson, K. G., Tucker, S. P., & Reece, P. A. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother. 2004; 48(5), 1766-1772. Bible, J. M., Iturriza-Gomara, M., Megson, B., Brown, D., Pantelidis, P., Earl, P., Bendig, J., & Tong, C. Y. Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol. 2008; 46(10), 3192-3200. Blomberg, J., Lycke, E., Ahlfors, K., Johnsson, T., Wolontis, S., & von Zeipel, G. Letter: New enterovirus type associated with epidemic of aseptic meningitis and-or hand, foot, and mouth disease. Lancet. 1974; 2(7872), 112. Brown, B. A., Oberste, M. S., Alexander, J. P., Jr., Kennett, M. L., & Pallansch, M. A. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol. 1999; 73(12), 9969-9975. Cardosa, M. J., Perera, D., Brown, B. A., Cheon, D., Chan, H. M., Chan, K. P., Cho, H., & McMinn, P. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg Infect Dis. 2003; 9(4), 461-468. Chakraborty, R., Iturriza-Gómara, M., Musoke, R., Palakudy, T., D'Agostino, A., & Gray, J. An epidemic of enterovirus 71 infection among HIV-1-infected orphans in Nairobi. 2004; 18(14), 1968-1970. Chan, L. G., Parashar, U. D., Lye, M. S., Ong, F. G., Zaki, S. R., Alexander, J. P., Ho, K. K., Han, L. L., Pallansch, M. A., Suleiman, A. B., Jegathesan, M., & Anderson, L. J. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis. 2000; 31(3), 678-683. Chang, C. S., Lin, Y. T., Shih, S. R., Lee, C. C., Lee, Y. C., Tai, C. L., Tseng, S. N., & Chern, J. H. Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives. J Med Chem. 2005; 48(10), 3522-3535. Chang, L. Y. Enterovirus 71 in Taiwan. Pediatr Neonatol. 2008; 49(4), 103-112. Chang, L. Y., King, C. C., Hsu, K. H., Ning, H. C., Tsao, K. C., Li, C. C., Huang, Y. C., Shih, S. R., Chiou, S. T., Chen, P. Y., Chang, H. J., & Lin, T. Y. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002; 109(6), e88. Chang, L. Y., Lee, C. Y., Kao, C. L., Fang, T. Y., Lu, C. Y., Lee, P. I., & Huang, L. M. Hand, foot and mouth disease complicated with central nervous system involvement in Taiwan in 1980-1981. J Formos Med Assoc. 2007; 106(2), 173-176. Chang, L. Y., Lin, T. Y., Hsu, K. H., Huang, Y. C., Lin, K. L., Hsueh, C., Shih, S. R., Ning, H. C., Hwang, M. S., Wang, H. S., & Lee, C. Y. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet. 1999; 354(9191), 1682-1686. Chang, L. Y., Tsao, K. C., Hsia, S. H., Shih, S. R., Huang, C. G., Chan, W. K., Hsu, K. H., Fang, T. Y., Huang, Y. C., & Lin, T. Y. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA. 2004; 291(2), 222-227. Chen, T. C., Liu, S. C., Huang, P. N., Chang, H. Y., Chern, J. H., & Shih, S. R. Antiviral activity of pyridyl imidazolidinones against enterovirus 71 variants. J Biomed Sci. 2008; 15(3), 291-300. Chen, X., Wang, C., Xu, L., Chen, X., Wang, W., Yang, G., Tan, R. X., Li, E., & Jin, Y. A laboratory evaluation of medicinal herbs used in china for the treatment of hand, foot, and mouth disease. Evid Based Complement Alternat Med. 2013; 2013, 504563. Chern, J. H., Shia, K. S., Hsu, T. A., Tai, C. L., Lee, C. C., Lee, Y. C., Chang, C. S., Tseng, S. N., & Shih, S. R. Design, synthesis, and structure-activity relationships of pyrazolo[3,4-d]pyrimidines: a novel class of potent enterovirus inhibitors. Bioorg Med Chem Lett. 2004; 14(10), 2519-2525. Chiang, L. C., Chiang, W., Chang, M. Y., Ng, L. T., & Lin, C. C. Antiviral activity of Plantago major extracts and related compounds in vitro. Antiviral Res. 2002; 55(1), 53-62. Chiang, L. C., Ng, L. T., Cheng, P. W., Chiang, W., & Lin, C. C. Antiviral activities of extracts and selected pure constituents of Ocimum basilicum. Clin Exp Pharmacol Physiol. 2005; 32(10), 811-816. Chiu, C. H., Chu, C., He, C. C., & Lin, T. Y. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect. 2006; 8(7), 1671-1678. Chiu, Y. H., Chan, Y. L., Tsai, L. W., Li, T. L., & Wu, C. J. Prevention of human enterovirus 71 infection by kappa carrageenan. Antiviral Res. 2012; 95(2), 128-134. Choi, H. J., Song, J. H., Park, K. S., & Baek, S. H. In vitro anti-enterovirus 71 activity of gallic acid from Woodfordia fruticosa flowers. Lett Appl Microbiol. 2010; 50(4), 438-440. Chonmaitree, T., Menegus, M. A., Schervish-Swierkosz, E. M., & Schwalenstocker, E. Enterovirus 71 infection: report of an outbreak with two cases of paralysis and a review of the literature. Pediatrics. 1981; 67(4), 489-493. Chou, A. H., Liu, C. C., Chang, C. P., Guo, M. S., Hsieh, S. Y., Yang, W. H., Chao, H. J., Wu, C. L., Huang, J. L., Lee, M. S., Hu, A. Y., Lin, S. C., Huang, Y. Y., Hu, M. H., Chow, Y. H., Chiang, J. R., Chang, J. Y., & Chong, P. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One. 2012; 7(4), e34834. Chu, P. Y., Lin, K. H., Hwang, K. P., Chou, L. C., Wang, C. F., Shih, S. R., Wang, J. R., Shimada, Y., & Ishiko, H. Molecular epidemiology of enterovirus 71 in Taiwan. Arch Virol. 2001; 146(3), 589-600. Chumakov, M., Voroshilova, M., Shindarov, L., Lavrova, I., Gracheva, L., Koroleva, G., Vasilenko, S., Brodvarova, I., Nikolova, M., Gyurova, S., Gacheva, M., Mitov, G., Ninov, N., Tsylka, E., Robinson, I., Frolova, M., Bashkirtsev, V., Martiyanova, L., & Rodin, V. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol. 1979; 60(3-4), 329-340. Chung, Y. C., Ho, M. S., Wu, J. C., Chen, W. J., Huang, J. H., Chou, S. T., & Hu, Y. C. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008; 26(15), 1855-1862. Cui, S., Wang, J., Fan, T., Qin, B., Guo, L., Lei, X., Wang, J., Wang, M., & Jin, Q. Crystal structure of human enterovirus 71 3C protease. J Mol Biol. 2011; 408(3), 449-461. de Amorin, A., Borba, H. R., Carauta, J. P., Lopes, D., & Kaplan, M. A. Anthelmintic activity of the latex of Ficus species. J Ethnopharmacol. 1999; 64(3), 255-258. De Palma, A. M., Thibaut, H. J., van der Linden, L., Lanke, K., Heggermont, W., Ireland, S., Andrews, R., Arimilli, M., Al-Tel, T. H., De Clercq, E., van Kuppeveld, F., & Neyts, J. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother. 2009; 53(5), 1850-1857. Diana, G. D., McKinlay, M. A., Otto, M. J., Akullian, V., & Oglesby, C. [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. Journal of Medicinal Chemistry. 1985; 28(12), 1906-1910. Dong, C., Wang, J., Liu, L., Zhao, H., Shi, H., Zhang, Y., Jiang, L., & Li, Q. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Hum Vaccin. 2010; 6(12), 1028-1037. Dragovich, P. S., Prins, T. J., Zhou, R., Webber, S. E., Marakovits, J. T., Fuhrman, S. A., Patick, A. K., Matthews, D. A., Lee, C. A., Ford, C. E., Burke, B. J., Rejto, P. A., Hendrickson, T. F., Tuntland, T., Brown, E. L., Meador, J. W., 3rd, Ferre, R. A., Harr, J. E., Kosa, M. B., & Worland, S. T. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem. 1999; 42(7), 1213-1224. Eloff, J. N. Quantification the bioactivity of plant extracts during screening and bioassay guided fractionation. Phytomedicine. 2004; 11(4), 370-371. Fernandez-Miragall, O., Lopez de Quinto, S., & Martinez-Salas, E. Relevance of RNA structure for the activity of picornavirus IRES elements. Virus Res. 2009; 139(2), 172-182. Foo, D. G., Alonso, S., Chow, V. T., & Poh, C. L. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007; 9(11), 1299-1306. Garozzo, A., Cutri, C. C., Castro, A., Tempera, G., Guerrera, F., Sarva, M. C., & Geremia, E. Anti-rhinovirus activity of 3-methylthio-5-aryl-4-isothiazolecarbonitrile derivatives. Antiviral Res. 2000; 45(3), 199-210. Genovese, D., Conti, C., Tomao, P., Desideri, N., Stein, M. L., Catone, S., & Fiore, L. Effect of chloro-, cyano-, and amidino-substituted flavanoids on enterovirus infection in vitro. Antiviral Res. 1995; 27(1-2), 123-136 Gilbert, G. L., Dickson, K. E., Waters, M. J., Kennett, M. L., Land, S. A., & Sneddon, M. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J. 1988; 7(7), 484-488. Guimaraes, A. G., Quintans, J. S., & Quintans, L. J., Jr. Monoterpenes with analgesic activity--a systematic review. Phytother Res. 2013; 27(1), 1-15. Hagiwara, A., Tagaya, I., & Yoneyama, T. Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology. 1978; 9(1), 60-63. Heinz, B. A., & Vance, L. M. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. J Virol. 1996; 70(7), 4854-4857. Ho, M., Chen, E. R., Hsu, K. H., Twu, S. J., Chen, K. T., Tsai, S. F., Wang, J. R., & Shih, S. R. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999; 341(13), 929-935. Horng, Jim-Tong, Jan, Jia-Tsrong, Wong, Wen-Rou, Tsai, Hui-Ping, Jheng, Jia-Rong, Liu, Yi-Chun, & Lin, Tzou-Yien. Anti-Enterovirus 71 Activity Screening of Chinese Herbs with Anti-Infection and Inflammation Activities. The American Journal of Chinese Medicine. 2009; 37(01), 143-158 Horng, Jim-Tong, Tai, Pei-Ju, Lin, Kwang-Huei, Chang, Yu-Kaung, Leu, Yann-Lii, Pan, Tai-Long, & Wu, Bin-Wen. Antiviral Effects of Salvia miltiorrhiza (Danshen) Against Enterovirus 71. The American Journal of Chinese Medicine. 2007; 35(01), 153-168. Hsiung, Gueh Djen, Fong, C.K.Y., & Landry, M.L. Hsiung's Diagnostic Virology: As Illustrated by Light and Electron Microscopy: Yale University Press. 1994. Hsu, B. M., Chen, C. H., & Wan, M. T. Prevalence of enteroviruses in hot spring recreation areas of Taiwan. FEMS Immunol Med Microbiol. 2008; 52(2), 253-259. Hsu, Hsing-Wen, Wang, Jen-Hsien, Liu, Chaio-Li, Chen, Chin-Shuh, & Wang, Yuan-Chuen. Anti-enterovirus 71 activity screening of Taiwanese folk medicinal plants and immune modulation of Ampelopsis brevipedunculata (Maxim.) Trautv against the virus. African Journal of Microbiology Research. 2011; 5(17). Huang, C. C., Liu, C. C., Chang, Y. C., Chen, C. Y., Wang, S. T., & Yeh, T. F. Neurologic complications in children with enterovirus 71 infection. N Engl J Med. 1999; 341(13), 936-942. Hung, H. C., Chen, T. C., Fang, M. Y., Yen, K. J., Shih, S. R., Hsu, J. T., & Tseng, C. P. Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid. J Antimicrob Chemother. 2010; 65(4), 676-683. International Committee on Taxonomy of Viruses., King, Andrew, & ScienceDirect (Online service). Virus taxonomy ninth report of the International Committee on Taxonomy of Viruses. 2011. Retrieved from http://www.sciencedirect.com/science/book/9780123846846 Ishimaru, Y., Nakano, S., Yamaoka, K., & Takami, S. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child. 1980; 55(8), 583-588. Iwai, M., Masaki, A., Hasegawa, S., Obara, M., Horimoto, E., Nakamura, K., Tanaka, Y., Endo, K., Tanaka, K., Ueda, J., Shiraki, K., Kurata, T., & Takizawa, T. Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis. 2009; 62(4), 254-259. Jee, Y. M., Cheon, D. S., Kim, K., Cho, J. H., Chung, Y. S., Lee, J., Lee, S. H., Park, K. S., Lee, J. H., Kim, E. C., Chung, H. J., Kim, D. S., Yoon, J. D., & Cho, H. W. Genetic analysis of the VP1 region of human enterovirus 71 strains isolated in Korea during 2000. Arch Virol. 2003; 148(9), 1735-1746. Khetsuriani, N., Lamonte-Fowlkes, A., Oberst, S., Pallansch, M. A., Centers for Disease, Control, & Prevention. Enterovirus surveillance--United States, 1970-2005. MMWR Surveill Summ. 2006; 55(8), 1-20. Kitajima, J., Kimizuka, K., & Tanaka, Y. Three new sesquiterpenoid glucosides of Ficus pumila fruit. Chem Pharm Bull (Tokyo). 2000; 48(1), 77-80. Kitajima, Junichi, Kimizuka, Kaoru, Arai, Masanobu, & Tanaka, Yasuko. Constituents of Ficus pumila Leaves. Chemical & pharmaceutical bulletin. 1998; 46(10), 1647-1649. Kitajima, Junichi, Kimizuka, Kaoru, & Tanaka, Yasuko. New Dammarane-Type Acetylated Triterpenoids and Their Related Compounds of Ficus pumila Fruit. Chemical & pharmaceutical bulletin. 1999; 47(8), 1138-1140. Kitajima, Junichi, Kimizuka, Kaoru, & Tanaka, Yasuko. New Sterols and Triterpenoids of Ficus pumila Fruit. Chemical & pharmaceutical bulletin. 1998; 46(9), 1408-1411 Konishi, E., Yamaoka, M., Kurane, I., & Mason, P. W. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine. 2000; 18(11-12), 1133-1139. Kuo, C. J., Shie, J. J., Fang, J. M., Yen, G. R., Hsu, J. T., Liu, H. G., Tseng, S. N., Chang, S. C., Lee, C. Y., Shih, S. R., & Liang, P. H. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg Med Chem. 2008; 16(15), 7388-7398. Kuo, K. K., Chang, J. S., Wang, K. C., & Chiang, L. C. Water extract of Glycyrrhiza uralensis inhibited enterovirus 71 in a human foreskin fibroblast cell line. Am J Chin Med. 2009; 37(2), 383-394. Leong, Cheng Ning Abraham, Tako, Masakuni, Hanashiro, Isao, & Tamaki, Hajime. Antioxidant flavonoid glycosides from the leaves of Ficus pumila L. Food Chemistry. 2008; 109(2), 415-420. Li, Y. P., Liang, Z. L., Gao, Q., Huang, L. R., Mao, Q. Y., Wen, S. Q., Liu, Y., Yin, W. D., Li, R. C., & Wang, J. Z. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012; 30(22), 3295-3303. Li, Z. H., Li, C. M., Ling, P., Shen, F. H., Chen, S. H., Liu, C. C., Yu, C. K., & Chen, S. H. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis. 2008; 197(6), 854-857. Lin, C. W., Wu, C. F., Hsiao, N. W., Chang, C. Y., Li, S. W., Wan, L., Lin, Y. J., & Lin, W. Y. Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71. Int J Antimicrob Agents. 2008; 32(4), 355-359.. Lin, K. H., Hwang, K. P., Ke, G. M., Wang, C. F., Ke, L. Y., Hsu, Y. T., Tung, Y. C., Chu, P. Y., Chen, B. H., Chen, H. L., Kao, C. L., Wang, J. R., Eng, H. L., Wang, S. Y., Hsu, L. C., & Chen, H. Y. Evolution of EV71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup C4 of EV71. J Med Virol. 2006; 78(2), 254-262. Lin, T. Y., Twu, S. J., Ho, M. S., Chang, L. Y., & Lee, C. Y. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis. 2003; 9(3), 291-293. Lin, Y. J., Lai, C. C., Lai, C. H., Sue, S. C., Lin, C. W., Hung, C. H., Lin, T. H., Hsu, W. Y., Huang, S. M., Hung, Y. L., Tien, N., Liu, X., Chen, C. L., & Tsai, F. J. Inhibition of enterovirus 71 infections and viral IRES activity by Fructus gardeniae and geniposide. Eur J Med Chem. 2013; 62, 206-213. Lin, Y. L., Chen, L. K., Liao, C. L., Yeh, C. T., Ma, S. H., Chen, J. L., Huang, Y. L., Chen, S. S., & Chiang, H. Y. DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice. J Virol. 1998; 72(1), 191-200. Liu, J. N., Wang, W., Duo, J. Y., Hao, Y., Ma, C. M., Li, W. B., Lin, S. Z., Gao, X. Z., Liu, X. L., Xu, Y. F., Xu, W. B., Qin, C., & Zhang, L. F. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010; 28(46), 7444-7451. McMinn, P. C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002; 26(1), 91-107. McMinn, P., Lindsay, K., Perera, D., Chan, H. M., Chan, K. P., & Cardosa, M. J. Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia, Singapore, and Western Australia. J Virol. 2001; 75(16), 7732-7738. Melnick, J. L. Enterovirus type 71 infections: a varied clinical pattern sometimes mimicking paralytic poliomyelitis. Rev Infect Dis. 1984; 6 Suppl 2, S387-390. Melnick, J. L., Schmidt, N. J., Mirkovic, R. R., Chumakov, M. P., Lavrova, I. K., & Voroshilova, M. K. Identification of Bulgarian strain 258 of enterovirus 71. Intervirology. 1980; 12(6), 297-302. Meng, F. Y., Li, J. X., Li, X. L., Chu, K., Zhang, Y. T., Ji, H., Li, L., Liang, Z. L., & Zhu, F. C. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum Vaccin Immunother. 2012; 8(5), 668-674. Merovitz, Lisa, Demers, Ann-Marie, Newby, Diane, & McDonald, Jane. Enterovirus 71 Infections At A Canadian Center. The Pediatric Infectious Disease Journal. 2000; 19(8), 755. Miwa, C., Ohtani, M., Watanabe, H., Fujimoto, J., Kinbara, K., & Tanaka, H. Epidemic of hand, foot and mouth disease in Gifu Prefecture in 1978. Jpn J Med Sci Biol. 1980; 33(3), 167-180. Nagy, G., Takatsy, S., Kukan, E., Mihaly, I., & Domok, I. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol. 1982; 71(3), 217-227. Nasri, D., Bouslama, L., Pillet, S., Bourlet, T., Aouni, M., & Pozzetto, B. Basic rationale, current methods and future directions for molecular typing of human enterovirus. Expert Rev Mol Diagn. 2007; 7(4), 419-434. Newman, D. J., & Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007; 70(3), 461-477. Nishimura, Y., Shimojima, M., Tano, Y., Miyamura, T., Wakita, T., & Shimizu, H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009; 15(7), 794-797. Oberste, M. S., Penaranda, S., Maher, K., & Pallansch, M. A. Complete genome sequences of all members of the species Human enterovirus A. J Gen Virol. 2004; 85(Pt 6), 1597-1607. Ooi, M. H., Wong, S. C., Lewthwaite, P., Cardosa, M. J., & Solomon, T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010; 9(11), 1097-1105. Ortner, B., Huang, C. W., Schmid, D., Mutz, I., Wewalka, G., Allerberger, F., Yang, J. Y., & Huemer, H. P. Epidemiology of enterovirus types causing neurological disease in Austria 1999-2007: detection of clusters of echovirus 30 and enterovirus 71 and analysis of prevalent genotypes. J Med Virol. 2009; 81(2), 317-324. Park, Ji-Young, Kim, Jang Hoon, Kim, Young Min, Jeong, Hyung Jae, Kim, Dae Wook, Park, Ki Hun, Kwon, Hyung-Jun, Park, Su-Jin, Lee, Woo Song, & Ryu, Young Bae. Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases. Bioorganic & Medicinal Chemistry. 2012; 20(19), 5928-5935. Perez-Velez, C. M., Anderson, M. S., Robinson, C. C., McFarland, E. J., Nix, W. A., Pallansch, M. A., Oberste, M. S., & Glode, M. P. Outbreak of neurologic enterovirus type 71 disease: a diagnostic challenge. Clin Infect Dis. 2007; 45(8), 950-957. Qu, M., Li, J., Jia, L., Tan, X. J., Gao, Z. Y., Yan, H. Q., Guo, J., Li, X. T., Li, X. Y., Wang, Q. Y., Xu, W. B., & Huang, F. [Etiology of hand-foot-and-mouth disease and genetic characteristics of Coxsackievirus A16 in Beijing, 2009]. Bing Du Xue Bao. 2010; 26(6), 432-436. REED, L.J., & MUENCH, H. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS. American Journal of Epidemiology. 1938; 27(3), 493-497. Ragasa, C. Y., Juan, E., & Rideout, J. A. A triterpene from Ficus pumila. J Asian Nat Prod Res. 1999; 1(4), 269-275. Schmidt, N. J., Lennette, E. H., & Ho, H. H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974; 129(3), 304-309. Shang, L., Xu, M., & Yin, Z. Antiviral drug discovery for the treatment of enterovirus 71 infections. Antiviral Res. 2013; 97(2), 183-194. Shang, Qinghua, Xu, Hao, & Huang, Li. Tanshinone IIA: A Promising Natural Cardioprotective Agent. Evidence-Based Complementary and Alternative Medicine. 2012; 2012, 7. Shekhar, K., Lye, M. S., Norlijah, O., Ong, F., Looi, L. M., Khuzaiah, R., Marzuki, I., Hussein, I., Wong, S. L., Mohan, J., Sinniah, M., & Abu Bakar, S. Deaths in children during an outbreak of hand, foot and mouth disease in Peninsular Malaysia--clinical and pathological characteristics. Med J Malaysia. 2005; 60(3), 297-304. Shettima, AY., Karumi, Y., Sodipo, OA., Usman, H. & Tijjani, MA. Gas Chromatography–Mass Spectrometry (GC-MS) Analysis of Bioactive Components of Ethyl acetate Root Extract of Guiera senegalensis J.F. Gmel. 2013;3(03), 146-150. Shia, Kak-Shan, Li, Wen-Tai, Chang, Chung-Ming, Hsu, Ming-Chu, Chern, Jyh-Haur, Leong, Max K., Tseng, Sung-Nien, Lee, Chung-Chi, Lee, Yen-Chun, Chen, Shu-Jen, Peng, Kuan-Chang, Tseng, Huan-Yi, Chang, Yi-Ling, Tai, Chia-Liang, & Shih, Shin-Ru. Design, Synthesis, and Structure−Activity Relationship of Pyridyl Imidazolidinones:  A Novel Class of Potent and Selective Human Enterovirus 71 Inhibitors. Journal of Medicinal Chemistry. 2002; 45(8), 1644-1655. Shih, S. R., Stollar, V., & Li, M. L. Host factors in enterovirus 71 replication. J Virol. 2011; 85(19), 9658-9666. Shih, S. R., Tsai, K. N., Li, Y. S., Chueh, C. C., & Chan, E. C. Inhibition of enterovirus 71-induced apoptosis by allophycocyanin isolated from a blue-green alga Spirulina platensis. J Med Virol. 2003; 70(1), 119-125. Shimizu, H., Utama, A., Yoshii, K., Yoshida, H., Yoneyama, T., Sinniah, M., Yusof, M. A., Okuno, Y., Okabe, N., Shih, S. R., Chen, H. Y., Wang, G. R., Kao, C. L., Chang, K. S., Miyamura, T., & Hagiwara, A. Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997-1998. Jpn J Infect Dis. 1999; 52(1), 12-15. Solomon, T., Lewthwaite, P., Perera, D., Cardosa, M. J., McMinn, P., & Ooi, M. H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010; 10(11), 778-790. Sun, J. H., Yang, M., Wang, X. M., Xu, M., Liu, A. H., & Guo, D. A. Identification of tanshinones and their metabolites in rat bile after oral administration of TTE-50, a standardized extract of Salvia miltiorrhiza by HPLC-ESI-DAD-MSn. J Pharm Biomed Anal. 2007; 44(2), 564-574. Tagaya, I., & Tachibana, K. Epidemic of hand, foot and mouth disease in Japan, 1972-1973: difference in epidemiologic and virologic features from the previous one. Jpn J Med Sci Biol. 1975; 28(4), 231-234. Tagaya, I., Takayama, R., & Hagiwara, A. A large-scale epidemic of hand, foot and mouth disease associated with enterovirus 71 infection in Japan in 1978. Jpn J Med Sci Biol. 1981; 34(3), 191-196. Teng, Z., Tan, X. J., Shao, J. J., Zhang, Y., Kuang, X. Z., Zhang, X., & Xu, W. B. [Epidemiology and etiology of hand-foot-and-mouth disease in Shanghai, 2009]. Bing Du Xue Bao. 2010; 26(6), 437-442. Tsai, Fuu-Jen, Lin, Cheng-Wen, Lai, Chien-Chen, Lan, Yu-Ching, Lai, Chih-Ho, Hung, Chien-Hui, Hsueh, Kai-Chung, Lin, Ting-Hsu, Chang, Hebron C., Wan, Lei, Sheu, Jim Jinn-Chyuan, & Lin, Ying-Ju. Kaempferol inhibits enterovirus 71 replication and internal ribosome entry site (IRES) activity through FUBP and HNRP proteins. Food Chemistry. 2011; 128(2), 312-322. Tseng, C. C., Chang, L. Y., & Li, C. S. Detection of airborne viruses in a pediatrics department measured using real-time qPCR coupled to an air-sampling filter method. J Environ Health. 2010; 73(4), 22-28. Tu, P. V., Thao, N. T., Perera, D., Huu, T. K., Tien, N. T., Thuong, T. C., How, O. M., Cardosa, M. J., & McMinn, P. C. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis. 2007; 13(11), 1733-1741. Tung, W. S., Bakar, S. A., Sekawi, Z., & Rosli, R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther. 2007; 5, 6. van der Sanden, S., Koopmans, M., Uslu, G., van der Avoort, H., & Dutch Working Group for Clinical, Virology. Epidemiology of enterovirus 71 in the Netherlands, 1963 to 2008. J Clin Microbiol. 2009; 47(9), 2826-2833. Wang, C. Y., Huang, S. C., Zhang, Y., Lai, Z. R., Kung, S. H., Chang, Y. S., & Lin, C. W. Antiviral Ability of Kalanchoe gracilis Leaf Extract against Enterovirus 71 and Coxsackievirus A16. Evid Based Complement Alternat Med. 2012; 2012, 503165. Wang, Ching-Ying, Huang, Shun-Chueh, Lai, Zhen-Rung, Ho, Yu-Ling, Jou, Yu-Jen, Kung, Szu-Hao, Zhang, Yongjun, Chang, Yuan-Shiun, & Lin, Cheng-Wen. Eupafolin and Ethyl Acetate Fraction of Kalanchoe gracilis Stem Extract Show Potent Antiviral Activities against Enterovirus 71 and Coxsackievirus A16. Evidence-Based Complementary and Alternative Medicine. 2013; 2013, 11 Wang, J., Chen, X., Wang, W., Zhang, Y., Yang, Z., Jin, Y., Ge, H. M., Li, E., & Yang, G. Glycyrrhizic acid as the antiviral component of Glycyrrhiza uralensis Fisch. against coxsackievirus A16 and enterovirus 71 of hand foot and mouth disease. J Ethnopharmacol. 2013; 147(1), 114-121. Wang, S. M., Lei, H. Y., Huang, K. J., Wu, J. M., Wang, J. R., Yu, C. K., Su, I. J., & Liu, C. C. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis. 2003; 188(4), 564-570. Wang, X., Peng, W., Ren, J., Hu, Z., Xu, J., Lou, Z., Li, X., Yin, W., Shen, X., Porta, C., Walter, T. S., Evans, G., Axford, D., Owen, R., Rowlands, D. J., Wang, J., Stuart, D. I., Fry, E. E., & Rao, Z. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012; 19(4), 424-429. Wang, Y. C., & Huang, T. L. Anti-Helicobacter pylori activity of Plumbago zeylanica L. FEMS Immunol Med Microbiol. 2005; 43(3), 407-412. Watson, K. G., Brown, R. N., Cameron, R., Chalmers, D. K., Hamilton, S., Jin, B., Krippner, G. Y., Luttick, A., McConnell, D. B., Reece, P. A., Ryan, J., Stanislawski, P. C., Tucker, S. P., Wu, W. Y., Barnard, D. L., & Sidwell, R. W. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J Med Chem. 2003; 46(15), 3181-3184. Welch, Jon, Maclaran, Kate, Jordan, Tony, & Simmonds, Peter. Frequency, viral loads, and serotype identification of enterovirus infections in Scottish blood donors. Transfusion. 2003; 43(8), 1060-1066. Weng, K. F., Chen, L. L., Huang, P. N., & Shih, S. R. Neural pathogenesis of enterovirus 71 infection. Microbes Infect. 2010; 12(7), 505-510. Weng, Xin Chu, & Gordon, Michael H. Antioxidant activity of quinones extracted from tanshen (Salvia miltiorrhiza Bunge). Journal of Agricultural and Food Chemistry. 1992; 40(8), 1331-1336. WHO. A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD). 2011, 1-71. Witsø, Elisabet, Palacios, Gustavo, Rønningen, Kjersti S., Cinek, Ondrej, Janowitz, Diana, Rewers, Marian, Grinde, Bjørn, & Lipkin, W. Ian. Asymptomatic circulation of HEV71 in Norway. Virus Research. 2007; 123(1), 19-29. Wu, K. X., Ng, M. M., & Chu, J. J. Developments towards antiviral therapies against enterovirus 71. Drug Discov Today. 2010; 15(23-24), 1041-1051. Wu, S. C., Liu, C. C., & Lian, W. C. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine. 2004; 22(29-30), 3858-3864. Yarosh, É A., & Nikonov, G. K. The coumarins of the genus Ficus. Chemistry of Natural Compounds. 1973; 9(2), 255-256. Yamayoshi, S., Yamashita, Y., Li, J., Hanagata, N., Minowa, T., Takemura, T., & Koike, S. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009; 15(7), 798-801. Yang, B., Chuang, H., & Yang, K. D. Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol J. 2009; 6, 141. Yi, L., Lu, J., Kung, H. F., & He, M. L. The virology and developments toward control of human enterovirus 71. Crit Rev Microbiol. 2011; 37(4), 313-327. Yu, H., Chen, W., Chang, H., Tang, R., Zhao, J., Gan, L., Liu, B., Chen, J., & Wang, M. Genetic analysis of the VP1 region of enterovirus 71 reveals the emergence of genotype A in central China in 2008. Virus Genes. 2010; 41(1), 1-4. Zhang H. J, Qiu M. H, Chen Y. G, Chen J. X, Sun Y, Wang C. F, Fong HHS. Plant Terpenes, in Natural Products, edited by Pezzuto, John and Kato, Massuo Jorge, in Encyclopedia of Life Support Systems (EOLSS), Developed under the Auspices of the UNESCO, Eolss Publishers, Oxford, UK, [http://www.eolss.net], in press. Zhang, X. N., Song, Z. G., Jiang, T., Shi, B. S., Hu, Y. W., & Yuan, Z. H. Rupintrivir is a promising candidate for treating severe cases of Enterovirus-71 infection. World J Gastroenterol. 2010; 16(2), 201-209. Zhang, Y., Zhu, Z., Yang, W., Ren, J., Tan, X., Wang, Y., Mao, N., Xu, S., Zhu, S., Cui, A., Zhang, Y., Yan, D., Li, Q., Dong, X., Zhang, J., Zhao, Y., Wan, J., Feng, Z., Sun, J., Wang, S., Li, D., & Xu, W. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J. 2010; 7, 94. Zhao, Jianglin, Lou, Jingfeng, Mou, Yan, Li, Peiqin, Wu, Jianyong, & Zhou, Ligang. Diterpenoid Tanshinones and Phenolic Acids from Cultured Hairy Roots of Salvia miltiorrhiza Bunge and Their Antimicrobial Activities. Molecules. 2011; 16(3), 2259-2267. Zheng, Z. M., He, P. J., Caueffield, D., Neumann, M., Specter, S., Baker, C. C., & Bankowski, M. J. Enterovirus 71 isolated from China is serologically similar to the prototype E71 BrCr strain but differs in the 5'-noncoding region. J Med Virol. 1995; 47(2), 161-167. Zhu, Q. C., Wang, Y., Liu, Y. P., Zhang, R. Q., Li, X., Su, W. H., Long, F., Luo, X. D., & Peng, T. Inhibition of enterovirus 71 replication by chrysosplenetin and penduletin. Eur J Pharm Sci. 2011; 44(3), 392-398.
摘要: 腸病毒71型 (Enterovirus 71, EV71) 於1969年美國加州首度分離出後,就一直在世界各地造成流行,其中以亞洲地區最為嚴重。1998年,台灣爆發了EV71大規模流行,超過一百五十萬人受感染,造成78個人死亡。不幸地,目前在臨床上並沒有有效的藥物或疫苗可以使用。在我們先前的相關研究顯示,薜荔具有良好抗腸病毒71型的活性,並由其95%乙醇萃取物分離出一活性成分—補骨脂酚 (Bakuchiol)。因此,本研究接續先前之研究,探討薜荔區分物抗腸病毒71型之活性成分。 首先,薜荔95%乙醇萃取物以 Amberlite XAD-7HP 分離得到11個活性區分 (IC50 = 4.6±0.1~ >160 μg/mL),其中區分 G的總活性 (Total activity =454 mL) 為最高,區分 J則具有最低的IC50 (4.6±0.1μg/mL)。接著區分 G 以 Sephadex LH-20管柱層析分離得到G-I~G-Ⅸ 等9個區分,其中區分 G-V 有最低的IC50 (10±0.1 μg/mL);區分G-V進行第一次矽膠管柱層析得到G-V-1~G-V-8等8個區分物,區分G-V-4有最低的IC50 ( 23.6±1.2 μg/mL);區分 G-V-4再以第二次矽膠管柱層析分離得到G-V-4-1~G-V-4-4等4個區分 (IC50 = 12.6±2.3~65.9±4.3 μg/mL)。區分 J 經第一次半製備型C18-HPLC層析得到J-1~J-3等3個區分 (IC50 = 6.4±0.4~20.0±0.0 μg/mL),區分 J-2再以第二次製備型C18-HPLC層析區分 J-2-3 (IC50 = 0.8±0.2 μg/mL)。其中之區分 G-V-4-1、G-V-4-2及J-2-3經由紫外光/可見光光譜儀、核磁共振光譜儀、液相串聯質譜儀及高解析質譜儀等圖譜之結果分別判斷為 Hexenyl isobutyl terephthlate、n-butyl isobutyl terephthalate 及 Tanshinone IIA。此3個化合物首次由薜荔被分離出來且首度報導具有抗EV71活性。丹參酮 IIA及補骨酯酚對EV71之抑制機轉包括預防病毒感染、直接殺死病毒、抑制病毒吸附宿主細胞及抑制病毒複製等作用,隨處理劑量增加,病毒抑制率也顯著上升 (p < 0.05),而呈現劑量依賴型抑制效果。
Since first isolated in California, USA in 1969, the epidemics of enterovirus 71 (EV71) have circulated worldwide, especially in Asia. In 1998, a large outbreak of EV71 occurred and more than 1.5 million cases were infected including 78 deaths. Unfortunately, so far, there are still no effective drugs or vaccines for clinical therapy. In our previous study, 95% ethanol extract of Ficus pumila L. exhibited significant anti-EV71 activity and an active compound named bakuchiol was isolated. Hence, following previous study, the purpose of my study was to isolate the active ingredients from fractions of Ficus pumila L. on anti-EV71 activity. 95% ethanol extract of Ficus pumila L. was firstly subjected to Amberlite XAD-7HP column chromatography to obtain eleven active fractions (Frs A~L;IC50=4.6±0.1~ >160 μg/mL). Among all fractions, the Fr. G showed the highest total activity (454 mL) and Fr. J showed the lowest IC50 (4.6±0.1μg/mL). Fr. G was further chromatographed on a Sephadex LH-20 column to obtain nine fractions (Frs. G-I~Ⅸ) and Fr. G-V showed the lowest IC50 (10±0.1 μg/mL) within these fractions. Fr G-V was purified by chromatography over silica gel column to yield eight fractions (Frs. G-V-1~8). Fr. G-V-4 had showed the lowest IC50 (23.6±1.2 μg/mL) within these fractions and was further purified by chromatography over silica gel column to yield four fractions (Frs. G-V-4-1~4;IC50 = 12.6±2.3~65.9±4.3 μg/mL). Fr J was separated by semi-preparative C18-HPLC to obtain three fractions (Frs. J-1~J-3;IC50 = 20.0±0.0~6.4±0.4 μg/mL) and Fr. J-2 was further separated by semi-preparative C18-HPLC to obtain Fr. J-2-3 (IC50 = 0.8±0.2 μg/mL). Hexenyl isobutyl terephthalate, n-butyl isobutyl terephthalate and tanshinone II were identified in Fr. G-V-4-1, G-V-4-2 and J-2-3, respectively Three anti-EV71 active compounds were first isolated and reported in Ficus pumila L. . Time-of-addition assay demonstrated the anti-EV71 mechanisms of Tanshinone IIA and Bakuchiol including the prevention of viral infection, inactivating virus and inhibition of EV71 replication.
URI: http://hdl.handle.net/11455/89806
文章公開時間: 10000-01-01
Appears in Collections:食品暨應用生物科技學系

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.